Downschedule decision on allergic rhinitis drugs

Bid to downschedule existing fixed-dose combination products containing both azelastine and fluticasone propionate rejected in interim decision An application to amend the existing S2 entries for azelastine and fluticasone propionate to include details for fixed-dose combination products containing both of these substances for use up to six months has been rejected by the Advisory Committee on

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacy growth: the traps
Next Show me the data: supporting medication adherence